News Quantified

PHAT – phathom pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Phathom Pharmaceuticals (PHAT) was upgraded by Barclays PLC from "equal weight" to "overweight". They now have a $18.00 price target on the stock, up from $16.00.

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]

Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]

Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]

Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]

5.0%

BEAT

-5.2%

BEAT

8.1%

BEAT

-18.0%

BEAT

Form S-8 Phathom Pharmaceuticals,

Form SCHEDULE 13G Phathom Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC

Form 4 Phathom Pharmaceuticals, For: Mar 10 Filed by: Parikh Asit

Form 4 Phathom Pharmaceuticals, For: Feb 27 Filed by: Breedlove Robert Charles

Form 10-K Phathom Pharmaceuticals, For: Dec 31

Top News Gainers

4/3 Form 4 Phathom Pharmaceuticals, For: Apr 01 Filed by: Kolchinsky Peter 13.1%

2/14 Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. 12.3%

12/23 Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection 11.1%

1/6 Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer 9.6%

10/24 Form S-1MEF Phathom Pharmaceuticals, 9.3%

1/27 Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD 6.9%

12/12 Form 3 Phathom Pharmaceuticals, For: Dec 02 Filed by: Parikh Asit 4.7%

4/9 Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference 2.6%

11/19 Phathom Pharmaceuticals (NASDAQ: PHAT) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 2.4%

11/25 Q3/2019 9/30/2019 EPS -9.300 ZacksConsensus N/A ActVsEst N/A - N/A 2.3%

Top News Decliners

3/17 Form 8-K Phathom Pharmaceuticals, For: Mar 11 -10.0%

3/20 Phathom Pharmaceuticals (NASDAQ: PHAT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -3.8%

10/26 Phathom Pharmaceuticals goes public [Reuters] -3.5%

3/19 Form 3 Phathom Pharmaceuticals, For: Mar 17 Filed by: Stenhouse Mark -3.3%

3/31 Form 4 Phathom Pharmaceuticals, For: Mar 27 Filed by: Kolchinsky Peter -2.9%

2/6 Form 3/A Phathom Pharmaceuticals, For: Feb 06 Filed by: Kolchinsky Peter -2.5%

11/6 Form SC 13D Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD -2.1%

10/28 Form S-8 Phathom Pharmaceuticals, -1.1%

2/14 Form SC 13G Phathom Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC -1.1%

12/2 Form 8-K Phathom Pharmaceuticals, For: Nov 30 -0.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day